BioSpace News Archive

Drug Development

Despite Stumbles, Bayer, BMS & Janssen Moving Forward with XIa Inhibitors

Factor XIa inhibitors developed by Bayer and the duo of BMS and Janssen Pharmaceuticals missed Phase II endpoints in data presented at ESC.

August 29, 2022
·
3 min read
·
Tristan Manalac
Drug Development

AstraZeneca’s Farxiga the First Drug to Lower Fatality for All Forms of Heart Failure

AstraZeneca reported a pre-specified pooled analysis from its Phase III trial of the diabetes drug Farxiga in patients with heart failure.

August 29, 2022
·
3 min read
·
Mark Terry
Policy

Space Mission Searches for Insights into High Radiation, Cancer

The Artemis I space mission hopes to provide researchers with a better understanding of the high levels of radiation on the body for cancer treatment and other applications.

August 29, 2022
·
2 min read
·
Alex Keown
Computer Engineers in the Life Sciences: How Technological Advancements are Increasing Demand

With technological advancements in the life science field comes a higher demand for professionals with tech backgrounds, specifically computer engineers, to help make it all happen.

August 29, 2022
·
5 min read
·
Christie Adams
Drug Development

Bayer’s Kerendia Shows Competitive Profile in Type 2 Diabetes-Related CKD

Phase III data shows the potential of Bayer’s Kerendia to reduce the risk of all-cause and cardiovascular mortality in type 2 diabetes patients with chronic kidney disease.

August 29, 2022
·
2 min read
·
Tristan Manalac
Prostate Health Market Size Worth USD 69.60 Billion in 2030

The global prostate health market size was USD 32.07 Billion in 2021 and is expected to register a revenue CAGR of 9.1% during the forecast period, according to the latest analysis by Emergen Research.

August 29, 2022
·
6 min read
Optimized Affinity CD38 CAR-NK Therapy Shows Early Promise in Multiple Myeloma

ONK Therapeutics announced Monday that its lead candidate showed potent anti-tumor activity both in-vivo and in-vitro versus multiple myeloma (MM)

August 29, 2022
·
2 min read
·
Vanessa Doctor, RN
Drug Development

Alnylam Scores Another RNAi Win with Mid-Phase IgAN Data

Alnylam Pharmaceuticals reported positive Phase II results for cemdisiran, an RNA interference (RNAi) drug developed to treat IgA nephropathy.

August 29, 2022
·
2 min read
·
Katherine Davis
Bio NC

Verona Pharma to Present at H.C. Wainwright 24th Annual Global Investment Conference

Verona Pharma plc, announces that senior management will present a company overview at the H.C. Wainwright 24th Annual Global Investment Conference on Monday, September 12, 2022 at 2:00 PM ET / 7:00 PM BST.

August 29, 2022
·
1 min read
Business

RaySearch Laboratories: Interim report April 1 - June 30, 2022

RaySearch signed an agreement with Region Västerbotten to provide RayStation to Norrlands universitetssjukhus.

August 29, 2022
·
3 min read